An interventional study of HIRT and HIET in COPD Exacerbation, sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Istituti Clinici Scientifici Maugeri SpA.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 12th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →5 of the 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA are open now, in 1 country. Recruiting first, the newest first:
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 40–85
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 50–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 64 is close to the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 50 across the 11 interventional studies, 101 across the 3 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.
4 of the studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720780Istituti Clinici Scientifici Maugeri SpARehabilitation Training With Music-support & Exercise Tolerance in COPD and CRF Patients. | 2026-12-31 |
| NCT03799354Istituti Clinici Scientifici Maugeri SpAStudy on Impact of Maximal Strength Training in Patients With COPD | 2027-02-28 |
| NCT05708443Istituti Clinici Scientifici Maugeri SpAEffect of Combined Endurance Training on ADL and Walking in COPD Patients | 2027-02-28 |
| NCT07302425Istituti Clinici Scientifici Maugeri SpAHigh-intensity Resistance Training in Post-exacerbation COPD | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies in Pulmonary Disease, Chronic Obstructive by Istituti Clinici Scientifici Maugeri SpA, from their registry updates:
This tab as a report to print or save as PDF → With an account.
After a COPD exacerbation, many individuals experience severe weakness in the leg muscles, especially the quadriceps. This weakness can make daily activities difficult and slow down recovery. Traditional respiratory rehabilitation usually focuses on endurance training, which is effective but often hard to tolerate soon after an exacerbation due to persistent symptoms and limited functional capacity.
This study aims to compare two early rehabilitation approaches during recovery from a COPD exacerbation: a maximal strength training (MST) programme using high loads and few repetitions, and a traditional endurance-based training programme.
The investigators aim to determine whether MST is easier to tolerate, especially in terms of breathlessness, and whether MST can improve muscle strength, efficiency, and overall exercise tolerance as well as or better than endurance training.
The results will help identify the most suitable rehabilitation strategy for individuals recovering from a COPD exacerbation, particularly for those who struggle with high-intensity endurance exercise.
Background
Exacerbations of chronic obstructive pulmonary disease (COPD) represent critical events in the disease trajectory, significantly increasing mortality, hospital readmissions, and reducing quality of life. Following an exacerbation, affected individuals frequently experience higher symptoms and functional decline, which may be either reversible or not.
Individuals recovering from COPD exacerbations often face profound peripheral muscle weakness, particularly in the quadriceps. This is attributed to systemic inflammation, corticosteroid use, chronic inactivity, and nutritional deficits during acute phases.
Current international guidelines advocate for pulmonary rehabilitation (PR) during the post-acute recovery phase of COPD. These programmes integrate exercise training, self-management education, psychological support, and pharmacological optimization. PR programmes must be tailored to each participant's clinical conditions, comorbidities, and needs.
The ideal timing of PR initiation after an acute exacerbation of COPD remains debated. Some evidence shows that early rehabilitation involving endurance training during hospitalization did not reduce readmission rates nor improve long-term physical capacity, and was associated with increased mortality at 12 months, compared to delayed PR. Consequently, guidelines recommend starting PR within three weeks after discharge from acute hospital care to mitigate any risk associated with early initiation during the acute phase.
Regarding modality, the core component of PR programmes is moderate to high-intensity endurance training, recommended as the gold standard to improve exercise tolerance, functional capacity, and health-related quality of life in stable COPD. However, high-intensity endurance sessions may be hard to tolerate for individuals recovering from an exacerbation, who still experience severe symptoms and marked limitations in daily activities.
Alternative types of training that allow the muscles to be trained without triggering marked dyspnoea and fatigue have been investigated. Previous evidence describes lower cardiorespiratory stress induced by resistance training compared with endurance training in individuals with COPD.
In the context of COPD exacerbations, resistance training initiated early during hospitalization has been shown to effectively prevent muscle deterioration, promote anabolic balance, and counteract catabolic processes without exacerbating systemic inflammation. Individuals undergoing resistance training demonstrated significant improvements in quadriceps strength and six-minute walking distance (6MWD), highlighting its potential as a core component of early PR during COPD exacerbation.
Additional evidence indicates that adding resistance training to endurance training during the post-exacerbation phase produces significant increases in muscle strength while yielding comparable benefits in dyspnoea, exercise capacity, and quality of life.
Therefore, resistance training appears feasible and safe both in the acute and post-acute phases of a COPD exacerbation, but whether strength programmes may allow training for individuals unable to tolerate high-intensity endurance sessions remains unknown.
Among resistance training programmes, maximal strength training (MST) has the potential to most effectively improve lower limb function. MST consists of exercising at high loads and few repetitions, requiring participants to develop maximal rate of force mobilization during the concentric phase. Evidence in stable COPD indicates that MST is safe, feasible, and significantly improves quadriceps rate of force development, mechanical efficiency, and effort tolerance.
Currently, no clear guideline exists for the protocol to be used for participants in the initial rehabilitation phase after exacerbation. In clinical practice, during the early phase of the rehabilitation pathway, a high percentage of individuals (estimated between 40% and 50%) are unable to perform endurance training according to the gold standard for stable COPD (intensity at 70% of maximum watt at incremental test).
For this reason, MST could represent a valid alternative for individuals who are not able or not yet able to tolerate high-intensity endurance training after an exacerbation. Due to the lower respiratory involvement associated with this type of training, the investigators hypothesize higher tolerance, greater improvements in dyspnoea and lower limb muscular efficiency, and similar changes in effort tolerance.
Primary aim
The primary objective of this study is to compare the effects of an early MST programme versus a conventional high-intensity endurance training programme on dyspnoea reduction when initiated shortly after hospital discharge for a COPD exacerbation.
Secondary aims
The secondary aims are to compare MST with high-intensity endurance training in terms of:
Impact of the disease and quality of life
Only for non-dropout participants:
Walking efficiency assessed by a dedicated treadmill test
Only after the last training session:
Satisfaction and acceptability of the training programmes
Material and Methods
Intervention
The rehabilitation programme will consist, for the first 15 sessions, of:
<!-- -->
High-Intensity Resistance Training (HIRT) - Experimental Group Participants will perform high-intensity strength training with progressive workload increases and low-intensity endurance training without progression.
Strength training will be performed on a horizontal leg press:
Possible side effects include delayed onset muscle soreness (DOMS), typically resolving within a short period.
HIRT will be performed in cycles of 2 days on and 1 day off.
Participants will perform:
After the 15-session programme, all participants will undergo T1 evaluation and continue with a combined programme (HIRT + HIET or HIET + HIRT) until discharge.
3. Dropouts Withdrawal will be defined if participants cannot complete the first training session without adverse events or side effects.
Criteria:
- HIRT group: at least 18/20 repetitions completed
- HIET group: at least 20 minutes of cycling with ≤1-minute interruption Participants unable to complete the first session will be classified as dropouts and continue training at low intensity.
4. Measures 4.1 Assessments at enrolment
<!-- -->
4.2 Outcome measures Collected at T0 (within 3 days of rehabilitation admission), T1 (after 15 sessions), and T2 (discharge).
Primary outcome
Secondary outcomes
Functional Capacity
Fatigue reduction
Muscle Strength and Structure
Neuromuscular fatigue (per-protocol only) Assessed using the interpolated twitch technique, including MVC, M waves, electrically stimulated resting force (Qtpot), and maximum voluntary activation (MVA).
Walking efficiency Determined through treadmill test at 3.0 km/h with metabolic analysis.
Acceptability and satisfaction Evaluated after last training session using a Likert scale (0-4).
Sample Size Sample size was calculated based on previous clinical data and expert review, estimating a need for 64 participants (32 per group) to detect meaningful differences in dyspnoea improvement.
Statistical Analysis Data will be analysed using descriptive statistics. Both intention-to-treat and per-protocol analyses will be applied. A two-way repeated-measures ANOVA will assess interaction effects between time (pre/post intervention) and group (resistance vs endurance). Statistical significance is set at p \< 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is the group performing high-intensity strength training on the leg press, combined with low-intensity cycling; it is the intervention study group.
Other: HIRT
This is the group performing high-intensity endurance training on the cycle ergometer, combined with low-intensity leg press; it is the active comparator study group (Active Comparator).
Other: HIET
The HIRT group will perform high-intensity strength training on a horizontal leg press, consisting of 4 sets of 5 repetitions at 90-95% of their maximum strength (1RM). Two-minute rests are given between sets, and the weight is increased by 2.5 kg whenever a patient can do more than 5 repetitions. Training focuses on quadriceps strength, from 90° to full extension. Sessions are scheduled 2 days on, 1 day off. This method has been shown to be safe, with mild muscle soreness as the most likely side effect. In addition, participants will perform low-intensity cycling at 20% of their maximum workload, which remains constant throughout the study, to maintain light endurance activity.
The HIET group will perform high-intensity endurance training on a cycle ergometer for 25 minutes at 70% of their maximum workload, with intensity progression of 10 watts if breathlessness is rated below 5 on the Borg scale. Each session includes a 3-minute warm-up and cool-down, with monitoring of heart rate, blood pressure, oxygen saturation, and symptoms. Participants train 5 days per week. Additionally, they perform low-intensity strength training on the horizontal leg press, 4 sets of 5 repetitions at 20% 1RM, 6-7 days per week, without progression. This combined program maintains both aerobic fitness and light muscle strength during conventional rehabilitation.
Dyspnea during daily activities measured by the Barthel Dyspnea Index (BDI)
Dyspnea (breathlessness) during routine daily activities will be measured using the Barthel Dyspnea Index (0-100; higher scores indicate greater dyspnea), a questionnaire that evaluates the severity of shortness of breath during common tasks such as walking, dressing, climbing stairs, and bathing. Each activity is scored, and higher scores indicate greater difficulty or breathlessness. The assessment is performed through patient self-report with guidance from a trained clinician. This measure provides a practical evaluation of how dyspnea affects functional independence in everyday life.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Distance walked on the Six-Minute Walk Test (6MWT)
Distance walked (meters) in the Six-Minute Walk Test (6MWT), measured to assess effort tolerance. The 6MWT evaluates submaximal functional exercise capacity by recording the total distance a patient can walk in six minutes along a flat corridor. It reflects global functional status and endurance.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Fatigue Severity Scale (FSS) total score
Fatigue severity measured using the Fatigue Severity Scale (FSS; 9 items scored 1-7; higher scores indicate greater fatigue; score range 9 - 63). The FSS assesses the impact of fatigue on daily life and functional performance. Patients rate statements related to fatigue intensity and its effect on physical and social activities.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Maximal Voluntary Contraction (MVC) of isometric quadriceps voluntary strength.
To evaluate whether HIRT, compared to HIET, increases quadriceps strength, measured as maximal voluntary contraction (MVC) in an isometric leg press position.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Lower Limb Strength Assessment with the 1-Repetition Maximum (1-RM) Test.
To evaluate whether HIRT, compared to HIET, improves lower-limb strength assessed with the 1-Repetition Maximum (1-RM) test on the horizontal leg press, recording the highest load lifted with rest intervals between trials.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Quadriceps muscle thickness (vastus lateralis) via ultrasound scanning
Quadriceps (vastus lateralis) muscle thickness, measured in millimeters (mm), assessed via ultrasound imaging. Measurements are taken at standardized anatomical landmarks with participants at rest to evaluate morphological adaptations following the training interventions.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Quadriceps pennation angle (vastus lateralis) via ultrasound scanning
Quadriceps (vastus lateralis) pennation angle, measured in degrees (°), assessed through ultrasound scanning. Changes in muscle architecture provide insights into structural adaptations associated with training-induced hypertrophy and force-production capacity.
Time frame: From randomization to the End of the program (up to 3 weeks)
Diaphragmatic thickness via ultrasound scanning
Diaphragm thickness measured in millimeters (mm) via ultrasound at end-expiration and end-inspiration. This assessment provides insights into structural changes of the diaphragm following the intervention.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Diaphragmatic excursion via ultrasound scanning
Diaphragmatic excursion, measured in millimeters (mm), assessed via ultrasound during quiet and deep breathing. Excursion reflects diaphragmatic mobility and functional performance.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Impact of the disease (COPD Assessment Test - CAT)
Disease impact assessed by the COPD Assessment Test (CAT; score 0-40; higher scores indicate worse disease impact). The CAT evaluates symptoms, activity limitations, and overall disease burden from the patient's perspective.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Health-related Quality of Life (MRF-26 questionnaire)
Health-related quality of life evaluated using the Maugeri Respiratory Failure 26 questionnaire (MRF-26; score 0-78; higher scores indicate worse quality of life). The questionnaire focuses on physical function, disability, and respiratory-related limitations..
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Maximal Voluntary Contraction (MVC)
Maximal Voluntary Contraction (MVC), measured Newtons (N), before and after the standardized fatigue task using dynamometry to quantify voluntary quadriceps force production.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Electrically stimulated resting force (Qtpot)
Electrically stimulated potentiated twitch force (Qtpot), measured in Newtons (N), used to assess peripheral muscle fatigue and contractile function.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Maximal Voluntary Activation (MVA)
Maximal voluntary activation (%) assessed via the interpolated twitch technique, quantifying central drive and central fatigue.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
M-wave amplitude
M-wave amplitude recorded through surface electromyography (EMG) and measured in millivolts (mV), to evaluate neuromuscular transmission and peripheral excitability before and after the fatigue task.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Walking efficiency (Walking Energy cost).
To evaluate whether HIRT, compared to HIET, improves walking efficiency, measured as the energy cost of walking on a treadmill for six minutes at 3 km/h, using oxygen consumption data collected via a portable metabolic analyzer.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Acceptability and satisfaction with the training.
To evaluate the acceptability and satisfaction of participants with the training programs, assessed using a Likert scale from 0 (completely unsatisfied) to 4 (very high satisfaction) after the last training session.
Time frame: From the date of randomization to the End of the program (up to 3 weeks)
Started Oct 2025 (actual). Primary completion is estimated for Oct 2027, 24 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Istituti Clinici Scientifici Maugeri SpA →